lapatinib has been researched along with pyrimethamine in 4 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (pyrimethamine) | Trials (pyrimethamine) | Recent Studies (post-2010) (pyrimethamine) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 5,088 | 738 | 1,047 |
| Protein | Taxonomy | lapatinib (IC50) | pyrimethamine (IC50) |
|---|---|---|---|
| Dihydrofolate reductase | Homo sapiens (human) | 3.1057 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.1007 | |
| Beta-hexosaminidase subunit alpha | Homo sapiens (human) | 6.8333 | |
| Beta-hexosaminidase subunit beta | Homo sapiens (human) | 6.4 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 4.3 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.0609 | |
| Dihydrofolate reductase | Pneumocystis carinii | 3.25 | |
| Dihydrofolate reductase | Candida albicans | 5 | |
| Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) | 15.615 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.39 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.3217 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum 3D7 | 2.48 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 2.0727 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Combrinck, JM; de Sousa, ACC; Egan, TJ; Maepa, K | 1 |
1 review(s) available for lapatinib and pyrimethamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for lapatinib and pyrimethamine
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites.
Topics: Antimalarials; Benzimidazoles; Binding Sites; Chloroquine; Drug Repositioning; Drug Resistance; Erythrocytes; Hemeproteins; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Lapatinib; Molecular Docking Simulation; Plasmodium falciparum; Pyrimethamine; Pyrimidines; Thermodynamics | 2020 |